Published in JAMA on October 12, 2011
Mutational landscape and significance across 12 major cancer types. Nature (2013) 14.91
The causes and consequences of genetic heterogeneity in cancer evolution. Nature (2013) 5.91
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64
Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res (2013) 3.25
Network-based stratification of tumor mutations. Nat Methods (2013) 3.12
Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol (2013) 2.71
Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell (2013) 2.34
Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol (2013) 2.24
Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair. Nature (2015) 2.04
Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis. Clin Cancer Res (2014) 1.97
Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy. Proc Natl Acad Sci U S A (2015) 1.72
Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. J Natl Cancer Inst (2015) 1.68
The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn) (2015) 1.59
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer (2015) 1.53
Disparities in ovarian cancer care quality and survival according to race and socioeconomic status. J Natl Cancer Inst (2013) 1.52
Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. JAMA Oncol (2015) 1.49
Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. J Natl Cancer Inst (2012) 1.48
Characterizing DNA methylation alterations from The Cancer Genome Atlas. J Clin Invest (2014) 1.27
Predicting time to ovarian carcinoma recurrence using protein markers. J Clin Invest (2013) 1.17
Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations. PLoS One (2013) 1.11
Comprehensive analysis of lncRNA expression profiles reveals a novel lncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer. Oncotarget (2016) 1.11
A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. Cancer Res (2015) 1.09
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discov (2015) 1.06
BRCAness: finding the Achilles heel in ovarian cancer. Oncologist (2012) 1.05
BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer. Epigenetics (2012) 1.05
BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. Br J Cancer (2013) 1.03
The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis. PLoS One (2014) 1.02
Structure-Function Of The Tumor Suppressor BRCA1. Comput Struct Biotechnol J (2012) 1.02
Cancer treatment according to BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol (2012) 1.01
PALB2: the hub of a network of tumor suppressors involved in DNA damage responses. Biochim Biophys Acta (2014) 1.01
The role of BRCA1 and BRCA2 in prostate cancer. Asian J Androl (2012) 1.00
Tumour suppressor genes in chemotherapeutic drug response. Biosci Rep (2012) 0.99
The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2. Oncotarget (2015) 0.97
Topoisomerase IIα in chromosome instability and personalized cancer therapy. Oncogene (2014) 0.97
An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer. Nat Commun (2015) 0.96
Major clinical research advances in gynecologic cancer in 2012. J Gynecol Oncol (2013) 0.96
Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy. Prostate Cancer Prostatic Dis (2013) 0.95
Key nodes of a microRNA network associated with the integrated mesenchymal subtype of high-grade serous ovarian cancer. Chin J Cancer (2015) 0.92
Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival. Cancer Genet (2012) 0.90
Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer. Pharmacogenomics (2012) 0.89
Predictive modeling using a somatic mutational profile in ovarian high grade serous carcinoma. PLoS One (2013) 0.87
A novel reannotation strategy for dissecting DNA methylation patterns of human long intergenic non-coding RNAs in cancers. Nucleic Acids Res (2014) 0.87
Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma. Gynecol Oncol (2012) 0.86
Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations. Clin Exp Metastasis (2013) 0.86
miR-506: a regulator of chemo-sensitivity through suppression of the RAD51-homologous recombination axis. Chin J Cancer (2015) 0.86
Translational genomics in cancer research: converting profiles into personalized cancer medicine. Cancer Biol Med (2013) 0.85
A reliable method for the detection of BRCA1 and BRCA2 mutations in fixed tumour tissue utilising multiplex PCR-based targeted next generation sequencing. BMC Clin Pathol (2015) 0.85
Clinical implications of using molecular diagnostics for ovarian cancers. Ann Oncol (2013) 0.85
Inherited variation in the PARP1 gene and survival from melanoma. Int J Cancer (2014) 0.85
New hypothesis on pathogenesis of ovarian cancer lead to future tailored approaches. Biomed Res Int (2013) 0.84
Personalising pancreas cancer treatment: When tissue is the issue. World J Gastroenterol (2014) 0.82
Application of next-generation sequencing in clinical oncology to advance personalized treatment of cancer. Chin J Cancer (2012) 0.82
High levels of genomic aberrations in serous ovarian cancers are associated with better survival. PLoS One (2013) 0.82
Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing. Gynecol Oncol (2012) 0.81
Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer. Chin J Cancer (2015) 0.81
Ovarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a Challenge. Front Oncol (2015) 0.81
Will Chinese ovarian cancer patients benefit from knowing the BRCA2 mutation status? Chin J Cancer (2011) 0.81
Clinical features and outcomes of germline mutation BRCA1-linked versus sporadic ovarian cancer patients. Hered Cancer Clin Pract (2016) 0.81
Dysregulation of X chromosome inactivation in high grade ovarian serous adenocarcinoma. PLoS One (2015) 0.80
Unwrapping the implications of BRCA1 and BRCA2 mutations in ovarian cancer. JAMA (2012) 0.80
Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases. PLoS One (2013) 0.80
DNA methylation changes in epithelial ovarian cancer histotypes. Genomics (2015) 0.80
Systematically Prioritizing Functional Differentially Methylated Regions (fDMRs) by Integrating Multi-omics Data in Colorectal Cancer. Sci Rep (2015) 0.80
New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study. J Med Genet (2016) 0.80
Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. Biomark Res (2015) 0.79
Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing. J Gynecol Oncol (2017) 0.79
Risk prediction model for epithelial ovarian cancer using molecular markers and clinical characteristics. J Ovarian Res (2015) 0.79
A genomic instability score in discriminating nonequivalent outcomes of BRCA1/2 mutations and in predicting outcomes of ovarian cancer treated with platinum-based chemotherapy. PLoS One (2014) 0.79
BRCA2 and TP53 collaborate in tumorigenesis in zebrafish. PLoS One (2014) 0.79
BRCA1 promoter hypermethylation in sporadic epithelial ovarian carcinoma: Association with low expression of BRCA1, improved survival and co-expression of DNA methyltransferases. Oncol Lett (2014) 0.78
Ovarian cancer in 2011: Mutations and non-inferiority analyses show a way forward. Nat Rev Clin Oncol (2011) 0.78
Binning somatic mutations based on biological knowledge for predicting survival: an application in renal cell carcinoma. Pac Symp Biocomput (2015) 0.78
Comparison of Clinical Outcomes of BRCA1/2 Pathologic Mutation, Variants of Unknown Significance, or Wild Type Epithelial Ovarian Cancer Patients. Cancer Res Treat (2016) 0.78
Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. Expert Opin Pharmacother (2013) 0.78
Identifying aggressive forms of endometrioid-type endometrial cancer: new insights into molecular subtyping. Expert Rev Anticancer Ther (2014) 0.78
3'-Phosphoadenosine 5'-phosphosulfate synthase 1 (PAPSS1) knockdown sensitizes non-small cell lung cancer cells to DNA damaging agents. Oncotarget (2015) 0.77
Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer. Gynecol Oncol (2016) 0.77
Recent Advancements in Prognostic Factors of Epithelial Ovarian Carcinoma. Int Sch Res Notices (2014) 0.77
Biomarkers for prostate cancer: present challenges and future opportunities. Future Sci OA (2015) 0.77
BRCA1 and BRCA2 mutations in ovarian cancer. JAMA (2012) 0.77
BRCA1 and BRCA2 mutations in ovarian cancer. JAMA (2012) 0.77
Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer. Onco Targets Ther (2017) 0.77
Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas. Mod Pathol (2016) 0.76
Return of research results from pharmacogenomic versus disease susceptibility studies: what's drugs got to do with it? Pharmacogenomics (2012) 0.76
BRCA1 promoter methylation is a marker of better response to platinum-taxane-based therapy in sporadic epithelial ovarian cancer. J Cancer Res Clin Oncol (2014) 0.76
Biallelic BRCA2 Mutations Shape the Somatic Mutational Landscape of Aggressive Prostate Tumors. Am J Hum Genet (2016) 0.76
A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population. J Ovarian Res (2015) 0.76
BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study. J Ovarian Res (2016) 0.75
Defining variations in survival of BRCA1 and BRCA2 mutation carriers. JAMA (2011) 0.75
Molecular staging of gynecological cancer: What is the future? Best Pract Res Clin Obstet Gynaecol (2015) 0.75
Optimized Prediction of Extreme Treatment Outcomes in Ovarian Cancer. Cancer Inform (2016) 0.75
Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study. Front Oncol (2013) 0.75
Genetics. BRCA inequality. Nat Rev Cancer (2011) 0.75
Transcriptional profiling and dynamical regulation analysis identify potential kernel target genes of SCYL1-BP1 in HEK293T cells. Mol Cells (2014) 0.75
Angiogenic alterations associated with circulating neoplastic DNA in ovarian carcinoma. Transl Oncol (2012) 0.75
Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival. Ecancermedicalscience (2016) 0.75
A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer. Value Health (2017) 0.75
PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet (2003) 53.59
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science (2003) 13.19
Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell (2002) 9.61
Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst (1999) 8.15
Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med (1996) 7.09
Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science (2007) 6.77
BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell (2001) 6.75
Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst (2002) 6.58
Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response. Science (2007) 5.88
Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol Cell (2001) 5.59
Involvement of Brca2 in DNA repair. Mol Cell (1998) 4.41
Improved survival in women with BRCA-associated ovarian carcinoma. Cancer (2003) 3.96
Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA (2000) 3.69
Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst (2002) 3.65
The BRCA1/BARD1 heterodimer modulates ran-dependent mitotic spindle assembly. Cell (2006) 3.46
Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol (2008) 3.46
"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol (2008) 3.25
BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat Genet (2002) 3.11
What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol (2006) 2.69
CCDC98 is a BRCA1-BRCT domain-binding protein involved in the DNA damage response. Nat Struct Mol Biol (2007) 2.55
BRCA1-dependent ubiquitination of gamma-tubulin regulates centrosome number. Mol Cell Biol (2004) 2.46
Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol (1998) 2.24
CCDC98 targets BRCA1 to DNA damage sites. Nat Struct Mol Biol (2007) 2.24
The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med (2002) 1.97
Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining. Proc Natl Acad Sci U S A (2001) 1.97
Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol (2002) 1.60
BRCA1 participates in DNA decatenation. Nat Struct Mol Biol (2005) 1.59
Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res (1999) 1.51
Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer. Cancer Res (1996) 1.47
Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma. Cancer (2005) 1.45
Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res (1998) 1.36
BRCA1 regulates gamma-tubulin binding to centrosomes. Cancer Biol Ther (2007) 1.15
Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1. Clin Cancer Res (1998) 1.15
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem (2003) 15.88
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell (2006) 15.16
Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29
Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science (2011) 13.16
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 11.29
Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet (2010) 10.75
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet (2008) 10.74
The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health (2009) 9.79
Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell (2002) 9.13
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med (2008) 7.75
HSV-1 ICP34.5 confers neurovirulence by targeting the Beclin 1 autophagy protein. Cell Host Microbe (2007) 7.34
Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest (2009) 7.09
Probabilistic Boolean Networks: a rule-based uncertainty model for gene regulatory networks. Bioinformatics (2002) 6.90
Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg (2004) 6.75
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med (2009) 6.61
Evaluation of the bacterial diversity in the feces of cattle using 16S rDNA bacterial tag-encoded FLX amplicon pyrosequencing (bTEFAP). BMC Microbiol (2008) 6.28
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med (2006) 6.18
Pten regulates neuronal arborization and social interaction in mice. Neuron (2006) 6.11
SCAN: SNP and copy number annotation. Bioinformatics (2009) 5.96
Ecological impacts of invasive alien plants: a meta-analysis of their effects on species, communities and ecosystems. Ecol Lett (2011) 5.95
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol (2012) 5.82
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol (2011) 5.46
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
Breast-cancer risk in families with mutations in PALB2. N Engl J Med (2014) 4.97
The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Sci Transl Med (2010) 4.78
Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med (2013) 4.67
Sequence and analysis of rice chromosome 4. Nature (2002) 4.39
A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci U S A (2007) 4.35
Survey of bacterial diversity in chronic wounds using pyrosequencing, DGGE, and full ribosome shotgun sequencing. BMC Microbiol (2008) 4.30
The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer (2006) 4.27
Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res (2005) 4.24
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol (2013) 4.20
Concern Calmodulin kinase II and arrhythmias in a mouse model of cardiac hypertrophy. Circulation (2002) 4.16
Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia. J Clin Invest (2006) 4.06
Stargazin modulates AMPA receptor gating and trafficking by distinct domains. Nature (2005) 3.88
Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell (2008) 3.87
Structure of the immature dengue virus at low pH primes proteolytic maturation. Science (2008) 3.86
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol (2008) 3.85
Variation in virulence among clades of Escherichia coli O157:H7 associated with disease outbreaks. Proc Natl Acad Sci U S A (2008) 3.69
Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol (2008) 3.68
Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol (2008) 3.67
Conformational changes of the flavivirus E glycoprotein. Structure (2004) 3.66
Shell-isolated nanoparticle-enhanced Raman spectroscopy. Nature (2010) 3.64
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res (2004) 3.63
Structures of immature flavivirus particles. EMBO J (2003) 3.62
Function of C/EBPdelta in a regulatory circuit that discriminates between transient and persistent TLR4-induced signals. Nat Immunol (2009) 3.60
Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med (2012) 3.54
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol (2003) 3.51
De novo gene mutations highlight patterns of genetic and neural complexity in schizophrenia. Nat Genet (2012) 3.49
RNA interference in the clinic: challenges and future directions. Nat Rev Cancer (2010) 3.43
Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem Biol (2010) 3.38
Using expression profiling data to identify human microRNA targets. Nat Methods (2007) 3.37
Genetic architecture of transcript-level variation in humans. Am J Hum Genet (2008) 3.36
The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res (2010) 3.36
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol (2010) 3.30
Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature (2013) 3.27
Relation of hospital volume to colostomy rates and survival for patients with rectal cancer. J Natl Cancer Inst (2003) 3.21
Regulation of tumor angiogenesis by EZH2. Cancer Cell (2010) 3.10
Uncovering a macrophage transcriptional program by integrating evidence from motif scanning and expression dynamics. PLoS Comput Biol (2008) 3.02
Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet (2010) 3.02
Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature (2013) 3.00
Distal airway stem cells yield alveoli in vitro and during lung regeneration following H1N1 influenza infection. Cell (2011) 3.00
Precise segmental renal artery clamping under the guidance of dual-source computed tomography angiography during laparoscopic partial nephrectomy. Eur Urol (2012) 2.95
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol (2013) 2.94
High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol (2008) 2.92
Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice. J Neurosci (2009) 2.90
Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol (2011) 2.90
Rac function and regulation during Drosophila development. Nature (2002) 2.89
Polymicrobial nature of chronic diabetic foot ulcer biofilm infections determined using bacterial tag encoded FLX amplicon pyrosequencing (bTEFAP). PLoS One (2008) 2.87
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res (2006) 2.86
Endobronchial ultrasound-guided transbronchial needle aspiration for staging of lung cancer: a systematic review and meta-analysis. Eur J Cancer (2009) 2.85
Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res (2010) 2.80
Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One (2009) 2.79
Bacterial tag-encoded FLX amplicon pyrosequencing (bTEFAP) for microbiome studies: bacterial diversity in the ileum of newly weaned Salmonella-infected pigs. Foodborne Pathog Dis (2008) 2.77
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol (2011) 2.75
GTPase activation of elongation factor EF-Tu by the ribosome during decoding. EMBO J (2009) 2.71
Nitrogen fixation island and rhizosphere competence traits in the genome of root-associated Pseudomonas stutzeri A1501. Proc Natl Acad Sci U S A (2008) 2.70
Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol (2006) 2.68
Quantized anomalous Hall effect in magnetic topological insulators. Science (2010) 2.67
The mechanical behaviors of polytetrafluorethylene/Al/W energetic composites. J Phys Condens Matter (2009) 2.64
Human embryonic stem cell-derived GABA neurons correct locomotion deficits in quinolinic acid-lesioned mice. Cell Stem Cell (2012) 2.62
Blocking Scn10a channels in heart reduces late sodium current and is antiarrhythmic. Circ Res (2012) 2.61
Faster STORM using compressed sensing. Nat Methods (2012) 2.61
Trends in prevalence, awareness, management, and control of hypertension among United States adults, 1999 to 2010. J Am Coll Cardiol (2012) 2.57
CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res (2013) 2.57
Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One (2011) 2.57
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol (2008) 2.53
Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med (2009) 2.51
Computational analysis of bacterial RNA-Seq data. Nucleic Acids Res (2013) 2.50
Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res (2003) 2.50
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res (2005) 2.48
Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer (2003) 2.48
Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxin-DNA adducts and phenanthrene tetraols in a randomized clinical trial in He Zuo township, Qidong, People's Republic of China. Cancer Epidemiol Biomarkers Prev (2005) 2.45